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Abstract
Background: It is uncertain whether liberal glucose control in critically ill diabetic patients leads to increased
ketone production and ketoacidosis. Therefore, we aimed to assess the prevalence of ketosis, ketonuria and
ketoacidosis in critically ill diabetic patients treated in accordance with a liberal glycemic control protocol.
Methods: We performed a prospective observational cohort study of 60 critically ill diabetic patients with blood
and/or urine ketone bodies tested in ICU. All patients were treated according to a liberal glucose protocol targeting
a blood glucose level (BGL) between 10 and 14 mmol/l in a single tertiary intensive care unit in Australia. We
measured quantitative bedside blood 3-beta-hydroxybutyrate (β-OHB) and semi-quantitative urine ketones on ICU
admission and daily during ICU stay, for a maximum of 10 consecutive days.
Results: Median blood β-OHB level on admission was 0.3 (0.1, 0.8) mmol/l. Ketoacidosis was rare (3 %), but some
level of ketosis (β-OHB ≥0.6 mmol/l) was found in 38 patients (63 %) early during their ICU stay. However, there was
no significant difference in prevalence or severity of ketonemia and ketonuria among patients with BGL above
(permissive hyperglycemia) or below 10 mmol/l. On multivariable linear regression analysis there was no association
between blood ketone levels and BGL, HbA1c, lactate levels, hematocrit, catecholamine infusion or APACHE III
score. In contrast, blood ketone levels tended to be higher after cardiopulmonary bypass surgery (P = 0.06).
Conclusions: Liberal glycemic control in critically ill diabetic patients does not appear to be associated with a high
prevalence of ketoacidosis or ketonemia. Moreover, ketosis is typically present on admission and resolves rapidly.
Finally, cardiopulmonary bypass surgery may be an important trigger of ketone body production.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12615000216516; trial registration date 5
March 2015).
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Background
Current guidelines recommend using insulin to main-
tain a blood glucose level (BGL) between 6 and
10 mmol/l in critically ill patients [1–4]. However,
controlling glucose within this target range is associ-
ated with a relatively high rate of hypoglycemia [5]
and increased mortality [6] in diabetic patients espe-
cially if adapted to chronic hyperglycemia (glycated
hemoglobin A1c [HbA1c] >7 %). Therefore, a more
liberal glycemic approach (target BGL between 10
and 14 mmol/l) may be safer in patients with dia-
betes. Recent pilot studies have demonstrated that
such "permissive hyperglycemia" effectively reduces
the need for exogenous insulin administration [7].
Consequently, in response to the introduction of a liberal
glucose protocol in diabetic patients, the incidence of both
absolute hypoglycemia (BGL <3.9 mmol/l) and potentially
harmful relative hypoglycemia (an acute and marked de-
crease in glycaemia) may be reduced.
However, whether such liberal strategies lead to
relative insulin deficiency, accelerated ketone body
production and induce ketoacidosis is uncertain. In
addition to insulin deficiency, several other factors
may stimulate ketogenesis via beta-oxidation of free
fatty acids (FFA) in critically ill patients. Such factors
include fasting (a ubiquitous state in patients admit-
ted to the intensive care unit [ICU]), increased secre-
tion of counter-regulatory hormones (glucagon,
adrenaline, growth hormone and cortisol), administra-
tion of exogenous catecholamines (adrenaline and
noradrenaline) [8] and administration of parenteral
nutrition containing medium-chain triglycerides [9].
Furthermore, entry of acetyl coenzyme A into the
Krebs cycle may be impaired during critical illness
due to reduced oxaloacetate levels. Consequently,
more acetyl coenzyme will be used for synthesis of
ketone bodies [10]. Similarly, elevated levels of de-
aminated amino acids may feed ketogenesis. More-
over, although the mechanism is less clear, alkalosis
appears to stimulate ketogenesis, particularly in dia-
betic subjects [11]. Finally, elevated blood ketone
levels have been observed following cardiopulmonary
bypass surgery, especially when performed under
hypothermia [12]. Although, many of these factors
may co-exist in the ICU setting, their combined im-
pact on ketone body production is unknown.
Accordingly, we conducted a prospective observational
study to explore the incidence of ketosis, ketonuria and
ketoacidosis during liberal glucose management of critic-
ally ill diabetic patients. In addition, we aimed to assess
the association of chronic glycaemia (HbA1c), acute gly-
caemia, illness severity, alkalosis, catecholamine infusion
and cardiopulmonary bypass surgery with blood ketone
levels on ICU admission in such patients.
Methods
Data collection
We performed a prospective observational study in all
diabetic patients admitted to a single tertiary adult
ICU between 30 August and 17 November 2015. All
patients were treated in accordance with our local
protocol for diabetic patients targeting a blood glu-
cose levels (BGL) between 10 and 14 mmol/l and in
which BGLs above 14 mmol/l were treated with intra-
venous or subcutaneous insulin. The Austin Health
Human Research Ethics Committee approved the
study (approval number LNR/14/Austin/487, HREC
131217 and 120712) with a waiver for informed con-
sent. The study was performed in accordance with
the ethical standards laid down in the 1964 Declar-
ation of Helsinki and its later amendments.
For the purpose of this study, we excluded patients
admitted with diabetic ketoacidosis (DKA) or a hyper-
glycemic hyperosmolar state (HHS). We collected
demographic data, ICU admission diagnoses, type of
diabetes, insulin dependency, chronic medication and
Acute Physiology and Chronic Health Evaluation
(APACHE) III score. We obtained daily data on use
of renal replacement therapy (RRT), incidence of
acute liver failure, rate of adrenaline and noradren-
aline infusion, type and rate of enteral or parenteral
nutrition and insulin administration.
Blood and urine sample collection and analysis
We collected arterial blood gas (ABG) data and spot
urine samples for measurement of blood and urine
ketone levels as soon as possible after ICU admission.
Thereafter, we performed daily ketone measurement
early in the morning, which likely represents peak
ketone levels [13] and simultaneously tested urine
samples for ketonuria until ICU discharge or up to a
maximum of 10 days. We measured blood β-
hydroxybutyrate (β-OHB) using the Freestyle Optium
Xceed point-of-care meter (Abbott Diabetes Care Inc.,
Maidenhead, UK). Simultaneously, we measured
hematocrit since previous data suggest that point-of-
care platforms may overestimate β-OHB at subnormal
hematocrit levels [14]. Ketonuria was semi-quantified
using Combur-test® strips (Roche Diagnostics, Rotk-
reuz, Switzerland). ABG samples were analyzed using
the Radiometer ABL825 blood gas analyzer (Radiom-
eter Medical A/S, Brønshøj, Denmark). We analysed
HbA1c on ICU admission at our central laboratory,
using COBAS INTEGRA® 800 (Roche Diagnostics, In-
dianapolis, IN, USA).
Definitions
We categorized ketosis according to blood β-OHB levels
as absent (<0.6 mmol/l), mild (0.6–1.5 mmol/l), moderate
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(1.6–3 mmol/l) or marked (>3 mmol/l). Ketonuria was
semi-quantified as mild, moderate or marked for urine ke-
tone levels of 1–4 mmol/l, 5–14 mmol/l and ≥15 mmol/l,
respectively. The presence of ketoacidosis was assessed
using both definitions suggested by the American Diabetes
Association (ADA) and the Joint British Diabetes Society
(JBDS) [15, 16].
Statistical analysis
We analyzed data using STATA® version Stata/SE
13.1 (Stata Corp., College Station, TX, USA). Con-
tinuous variables were expressed as median (inter-
quartile range [IQR]) and categorical variables as n
(%). We compared continuous data using the Mann-
Whitney U test (two groups) or the Kruskal-Wallis
test (multiple groups). For categorical variables, we
used the chi-squared test or the Fisher’s exact test.
The Spearman’s rank correlation coefficient was cal-
culated to assess correlations. Changes over time for
BGLs and blood ketone levels during permissive
hyperglycemia (BGL 10–14 mmol/l) were tested by
repeated measures analysis of variance (RM-ANOVA)
using ICU day as the repeated measures variable. For
comparison of these variables’ change over time in
patients who did and did not receive insulin, an
interaction variable (between category [insulin ther-
apy, yes vs. no] and time) was introduced in the
RM-ANOVA model. We used multivariable linear re-
gression analysis to assess the relationship between
blood ketone levels on ICU admission and the fol-
lowing variables: APACHE III score (tertiles), on-
going catecholamine infusion (yes vs. no), HbA1c,
admission BGL, cardiopulmonary bypass surgery (yes
vs. no), admission hematocrit and admission blood
lactate level. Since insulin therapy may impact both
ketogenesis and BGLs we restricted the multivariable
linear regression analysis to patients not receiving in-




We studied 60 consecutive critically ill diabetic pa-
tients (17 [28 %] females) with a median (IQR) age of
66 (60, 74) years and a median APACHE III score of
60 (46, 76). Overall, 57 (95 %) patients had type 2
diabetes of whom 24 (42 %) were insulin-dependent
prior to ICU admission. Two patients were treated
with a sodium-glucose cotransporter-2 inhibitor be-
fore ICU admission; none developed ketosis or keto-
nuria in ICU. The majority (42 %) of patients were
admitted after cardiovascular surgery, of which 22 pa-
tients underwent cardiopulmonary bypass surgery
(during normothermia in all 22 patients). Three (5 %)
patients were admitted with acute liver failure and
one with acute alcohol intoxication. Four patients had
a history of chronic alcohol abuse.
A total of 46 (77 %) patients had a peak BGL
≥10 mmol/l during ICU admission. Compared to pa-
tients with a peak BGL <10 mmol/l (n = 14), patients
with a peak BGL ≥10 mmol/l were younger (P =
0.02), had higher HbA1c (7.0 [6.2, 7.8] % vs. 6.2 [5.9,
6.5] %, P = 0.009) and greater admission BGL (P =
0.01). Moreover, a higher proportion of patients with
peak BGL ≥10 mmol/l were prescribed chronic insulin
therapy (23 [50 %] patients vs. 1 [7 %] patient, P = 0.007).
However, we observed no significant differences in APA-
CHE III score, admission blood ketone levels, admission
blood lactate levels or hematocrit levels between the
two groups. A total of 21 (46 %) patients with peak
BGL ≥10 mmol/l and two (14 %) patients with peak
BGL <10 mmol/l received catecholamine infusion on
admission (P = 0.06). Admission alkalosis (pH >7.45)
was relatively uncommon and only six (10 %) patients
received enteral or parenteral nutrition on admission.
Median length of stay in ICU (3.7 [2.2, 6.2] days) and
in hospital (11 [6.7, 24] days) as well as ICU (8 %)
and hospital (10 %) mortality was similar in the two
groups (Table 1).
Glycemic control, ketonemia and ketonuria
We analysed 280 blood glucose measurements, 277
blood ketone measurements, 261 urine ketone measure-
ments and 276 hematocrit measurements obtained
within 8.3 (1.6, 12.0) hours after ICU admission and
daily until ICU discharge or day 10, whichever came
first. A total of 274 (99 %) hematocrit levels were below
normal (<40 %). Furthermore, hematocrit decreased sig-
nificantly over a maximum observation period of 10 days
in ICU (Additional file 1: Figure S1).
Overall, 27 of 46 (59 %) patients with a peak BGL
≥10 mmol/l required insulin to maintain their BGLs be-
tween 10 and 14 mmol/l. Of these 27 patients, 74 % had
preexisting insulin-dependent diabetes. In addition, 27 of
46 (59 %) patients with a peak BGL ≥10 mmol/l received
enteral and/or parenteral nutrition during ICU admis-
sion whereas only two (14 %) patients with a peak BGL
<10 mmol/l received such nutrition. Mean total caloric
intake progressively increased during ICU admission
(Additional file 1: Figure S2). Only one patient received
parenteral nutrition, which did not contain medium-
chain triglycerides (OliClinomel, Baxter Healthcare,
Deerfield, IL, USA). Insulin was not administered to pa-
tients with a peak BGL <10 mmol/l in ICU. Half of all
patients received catecholamine infusion (mainly nor-
adrenaline) while in ICU (Table 2).
Overall, 38 (63 %) patients showed some degree of ke-
tosis (β-OHB ≥0.6 mmol/l) during ICU admission (20
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Table 1 Baseline characteristics and outcomes for all diabetic patients and according to peak blood glucose level
Characteristic All patients Peak BGL ≥10 mmol/l Peak BGL <10 mmol/l P value
Number of patients 60 (100) 46 (77) 14 (23)
Age, years 66 (60, 74) 65 (56, 71) 74 (65, 80) 0.02
Female sex, n (%) 17 (28) 15 (33) 2 (14) 0.31
Weight, kg (n = 58) 84 (74, 100) 84 (78, 104) 83 (74, 100) 0.39
BMI, kg/m2 (n = 40) 31 (27, 34) 32 (28, 35) 28 (24, 31) 0.11
APACHE III score 60 (46, 76) 59 (46, 75) 62 (48, 79) 0.71
Type 1 diabetes, n (%) 3 (5) 3 (7) 0
Type 2 diabetes, n (%) 57 (95) 43 (93) 14 (100) 1.00
Type 2 diabetes treatment, n (%) 0.007
Diet only 8 (13) 5 (11) 6 (43)
Oral agent(s) only 25 (42) 18 (39) 7 (50)
Insulin only 11 (18) 10 (22) 1 (7)
Insulin + oral agent(s) 13 (22) 13 (28) 0
Non-operative admission diagnosis, n (%) 0.59
Cardiovascular 6 (10) 5 (26) 1 (14)
Sepsis 6 (10) 5 (26) 1 (14)
Respiratory 6 (10) 3 (16) 3 (43)
Renal/metabolic 6 (10) 5 (26) 1 (14)
Other 2 (3) 1 (5) 1 (14)
Operative admission diagnosis, n (%) 0.09
Cardiovascular 25 (42) 20 (74) 5 (71)
Gastrointestinal 6 (10) 6 (22) 1 (14)
Other 3 (5) 1 (4) 1 (14)
HbA1c on ICU admission, % 6.7 (6.0, 7.7) 7.0 (6.2, 7.8) 6.2 (5.9, 6.5) 0.009
Blood glucose on ICU admission, mmol/l 9.3 (7.6, 12) 10 (7.8, 13) 8.1 (7.4, 9.0) 0.01
Blood ketones on ICU admission, mmol/l 0.3 (0.1, 0.8) 0.3 (0.1, 0.8) 0.4 (0.2, 0.6) 0.99
Ketosis on ICU admission, n (%) 23 (39) 17 (38) 6 (43) 0.12
Ketonuria on ICU admission, n (%) (n = 57) 8 (14) 6 (13) 2 (17) 0.09
Lactate on ICU admission, mmol/l 1.6 (1.1, 2.3) 1.7 (1.2, 2.7) 1.2, (1.0, 2.0) 0.06
Hematocrit on ICU admission, % 27 (25, 31) 27 (25, 29) 32 (27, 35) 0.07
Alkalosis on ICU admissiona, n (%) 7 (12) 7 (15) 0
Catecholamine infusion on ICU admission, n (%) 23 (38) 21 (46) 2 (14) 0.06
Nutrition on ICU admission, n (%) 6 (10) 6 (13) 0
Acute liver failure, n (%) 3 (5) 2 (4) 1 (7) 0.56
Chronic alcohol abuse, n (%) 4 (7) 3 (7) 1 (7) 1.00
Acute alcohol intoxication, n (%) 1 (2) 1 (2) 0
ICU length of stay, days 3.7 (2.2, 6.2) 3.7 (2.3, 6.9) 3.4 (2.1, 3.8) 0.26
Hospital length of stay, days 11 (6.7, 24) 11 (7.2, 23) 13 (5.4, 24) 0.86
ICU mortality, n (%) 5 (8) 4 (9) 1 (7) 0.85
Hospital mortality, n (%) 6 (10) 5 (11) 1 (7) 0.68
Values are median (IQR) or n (%)
BGL blood glucose level, BMI body mass index, APACHE Acute Physiology and Chronic Health Evaluation, ICU intensive care unit
apH >7.45
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Table 2 Glycemic control, ketonemia, ketonuria and acid–base status of diabetic patients with and without permissive
hyperglycemia
Variable All patients Peak BGL Peak BGL P value
≥10 mmol/l <10 mmol/l
Number of patients, n (%) 60 (100) 46 (77) 14 (23)
No. of blood glucose measurements, n (%) 280 229 51
No. of blood glucose measurements per patient 4 (3, 7) 4 (3, 7) 3 (2, 5) 0.19
Peak glucose level, mmol/l 12.0 (10.0, 15.0) 14 (12, 17) 8.2 (7.4, 9.5) <0.001
Mean glucose level, mmol/l 10.0 (8.3, 13.0) 12 (9.5, 13) 7.1 (6.6, 8.3) <0.001
Min glucose level, mmol/l 8.0 (6.2, 9.4) 8.8 (7, 9.9) 6.2 (5.7, 7.5) 0.007
No. of blood ketone measurements, n (%) 277 228 49
No. of blood ketone measurements per patient 4 (3, 7) 4 (3, 7) 3 (2, 4) 0.11
Time between ICU admission until first measurement, hours 8.3 (1.6, 12) 8.9 (1.7, 13) 3.2 (1.5, 11) 0.02
Patients receiving insulin, n (%) 27 (45) 27 (59) 0
Intravenous insulin rate, units/h 2 (1, 2) 2 (1, 2) 0
Patients receiving nutrition, n (%) 29 (48) 27 (59) 2 (14)
Enteral nutrition, n (%) 28 (47) 26 (57) 2 (14)
Total parenteral nutrition, n (%) 2 (3.3) 2 (4.3) 0
Patients receiving catecholamine infusion, n (%) 30 (50) 27 (46) 3 (21) 0.03
Noradrenaline, n (%) 29 (48) 26 (57) 3 (21) 0.03
Maximum noradrenaline rate, μg/min 5.0 (2.0, 16) 7.5 (2.0, 16) 2.0 (1.0, 4.0) 0.11
Adrenaline, n (%) 7 (12) 7 (15) 0
Maximum adrenaline rate, μg/min 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) NA
Ketosis episodes >0.6 mmol/l, n (%) 79 (28.6) 63 (28) 16 (33) 0.43
Peak blood ketones, mmol/l 0.8 (0.3, 1.9) 0.85 (0.2, 1.9) 0.65 (0.3, 1.0) 0.32
Worst ketosis, n (%) 0.52
No ketosis (<0.6 mmol/l) 22 (36.7) 16 (35) 6 (42)
Mild (0.6–1.5 mmol/l) 20 (33.3) 15 (33) 5 (36)
Moderate (1.6–3.0 mmol/l) 11 (18.3) 8 (17) 3 (21)
Marked (>3.0 mmol/l) 7 (11.7) 7 (15) 0
Number of urine ketone measurements 261 215 46
Worst ketonuria, n (%) 0.51
No ketonuria 40 (66.7) 31 (67) 9 (64)
Mild (1+) 13 (21.7) 10 (22) 3 (21)
Moderate (2+) 6 (10) 5 (11) 1 (7)
Marked (3+) 1 (1.7) 0 1 (7)
Patients with alkalosisa, n (%) 25 (42) 20 (43) 5 (36) 0.76
Blood gas analysis, worst value during study period
pH 7.4 (7.3, 7.4) 7.3 (7.3, 7.4) 7.4 (7.3, 7.4) 0.32
Lactate, mmol/l 2.2 (1.6, 3.1) 2.3 (1.7, 3.4) 2 (1.4, 2.3) 0.15
Bicarbonate, mmol/l 22 (20, 24) 22 (19, 24) 25 (23, 26) 0.002
Chloride, mmol/l 108 (104, 111) 108 (104, 111) 105 (102, 108) 0.10
Sodium, mmol/l 136 (132, 138) 136 (132, 138) 136 (132, 136) 0.73
Albumin, g/l 26 (22, 30) 26 (21, 29) 29 (23, 30) 0.75
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[33 %] mild, 11 [18 %] moderate and seven [12 %] severe
ketosis). A total of 20 (33 %) patients had some degree
of ketonuria (13 [22 %] mild, six [10 %] moderate and
one [2 %] severe ketonuria). Additionally, 25 (42 %) pa-
tients had at least one episode of alkalosis (pH >7.45).
On crude comparison, we observed a similar prevalence
and severity of ketosis and ketonuria in patients with
peak BGL above and below 10 mmol/l. In contrast, pa-
tients with a peak BGL ≥10 mmol/l had lower bicarbon-
ate levels (P = 0.001) and base excess (P = 0.006).
However, only two out of 60 (3.3 %) patients (one pa-
tient in each group) fulfilled the criteria for ketoacidosis
according to the JBDS consensus criteria (no patients
developed ADA-defined ketoacidosis, Table 2). A de-
scription of these two individuals is provided in the Add-
itional file 1.
Patients with (n = 38) and without (n = 22) ketosis had
similar HbA1c levels (median HbA1c 6.7 % in both
groups, P = 0.72) whereas admission hematocrit levels
were higher in patients with ketosis (P = 0.046). A simi-
lar proportion of patients had insulin-dependent dia-
betes in the two groups (42 vs. 50 %). Moreover,
admission and peak BGLs did not differ significantly
(Additional file 1: Table S1 and S2).
In contrast, compared to patients with mild to moder-
ate ketosis (n = 31), insulin-dependent diabetes tended to
be more common (71 % vs. 35 %, P = 0.12), HbA1c was
significantly greater (8.2 % vs. 6.5 %, P <0.001) and ad-
mission hematocrit was lower (25 % vs. 30 %, P = 0.03)
among patients with severe ketosis (n = 7) (Additional
file 1: Table S3).
In patients with BGL ≥10 mmol/l, ketosis resolved
within 3–4 days irrespective of whether insulin was ad-
ministered or not (Fig. 1a) and despite persistent hyper-
glycemia according to protocol (Fig. 1b).
We found no significant correlation between admission
blood ketone levels and admission BGLs (Fig. 2a), HbA1c
levels (Fig. 2b), blood lactate levels (Fig. 2c), hematocrit
levels (Fig. 2d), or catecholamine infusion (Fig. 2e) in pa-
tients not receiving insulin (n = 43). In contrast, patients
in the mid-APACHE III tertile had lower admission blood
ketone levels than patients in the highest and lowest tertile
(Fig. 2f). Patients with alkalosis on admission had signifi-
cantly lower blood ketone levels than patients without al-
kalosis (P = 0.04) whereas patients admitted following
cardiopulmonary bypass surgery had significantly greater
blood ketone levels (median [IQR] 0.6 [0.2, 1.3] mmol/l vs.
0.2 [0.1, 0.7] mmol/l than patients without cardiopulmo-
nary bypass surgery, P = 0.049). On multivariable linear re-
gression analysis, restricted to patients not receiving
insulin (n = 43), we observed no independent association
between blood ketone levels and blood glucose levels,
HbA1c levels, blood lactate levels, hematocrit levels,
Table 2 Glycemic control, ketonemia, ketonuria and acid–base status of diabetic patients with and without permissive
hyperglycemia (Continued)
Base excess (BE), mmol/l −2.8 (−5, 0) −3 (−5, −1) 0.35 (−4, 1) 0.006
ADA ketoacidosis, n (%) 2/60 (3.3) 1/46 (2.2) 1/14 (7.1) 1.00
JBDS ketoacidosis, n (%) 0/60 (0)
Values are median (IQR) or n (%)

























































Fig. 1 Mean (SEM) blood ketone levels (a) and blood glucose levels
(b) in patients with (red line) and without (blue line) insulin therapy.
Only patients with a blood glucose level above 10 mmol/l at each time
point included. P values represent the between-group comparison on
repeated-measures analysis of variance
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catecholamine infusion or APACHE III score. However, a
trend towards greater blood ketone levels in patients ad-
mitted following cardiopulmonary bypass was observed in
the adjusted analysis (P = 0.06) (Table 3).
Discussion
Key findings
We performed a prospective observational study to ex-
plore the prevalence of ketonemia and ketonuria in critic-
ally ill diabetic patients treated within a liberal glycemic
control protocol. Overall, about two thirds of our patients
had some degree of ketosis (β-OHB ≥0.6 mmol/l) during
their ICU stay and 33 % had some degree of ketonuria.
However, ketosis in these critically ill diabetic patients
managed with liberal glycemic control was typically seen
in the first 24–48 hours of admission and appeared inde-
pendent of glucose control, HbA1c level and severity of
illness. Moreover, ketosis resolved in all patients
irrespective of whether insulin was given or not. Finally,
ketosis appeared more pronounced following cardiopul-
monary bypass surgery.
Relationship to previous studies
To our knowledge, this is the first study investigating
the prevalence of ketosis in critically ill diabetic patients
without acute diabetic ketoacidosis or hyperosmolar
hyperglycemic state. We are also the first to describe the
prevalence of ketosis in patients treated with a liberal
glucose protocol (BGL target 10–14 mmol/l).
In accordance with our results, a study of 32 ventilated
non-diabetic ICU patients with (n = 19) and without (n =
13) stress hyperglycemia (BGL up to 16 mmol/l) found no
relationship between breath acetone concentration and
BGL [17]. While in most patients (n = 11) breath acetone
concentration decreased after insulin administration, some
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Fig. 2 Correlation between blood ketone levels and blood glucose levels (a), HbA1c (b), lactate (c), hematocrit (d), catecholamine infusion (e) and
APACHE III quartiles (f) on ICU admission in patients not receiving insulin
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The two main ketone bodies, acetoacetate (AcAc) and
3-beta-hydroxybutyrate (β-OHB), usually circulate in
low concentrations (<0.5 mmol/l) in healthy adults [18].
Serum levels of β-OHB start to rise after 12–16 hours of
fasting (an essentially ubiquitous state in critically ill pa-
tients in the period surrounding ICU admission), reach-
ing 1–2 mmol/l after 2 days [19–21], and 6–8 mmol/l
after 2–3 weeks of starvation [22, 23].
Harano et al. [13] compared serum ketone levels be-
tween non-acutely ill type 1 (n = 117) and type 2 (n =
260) diabetic patients and 91 healthy subjects after an
overnight fast. In patients with type 1 diabetes, ketone
bodies were higher despite normal fasting BGL and in-
creased proportionally to the BGL in hyperglycemic in-
dividuals. In type 2 diabetics, however, the authors
found only a weak correlation between fasting plasma
glucose and ketonemia with serum ketone levels rarely
exceeding 2 mmol/l. Interestingly, a post-prandial reduc-
tion in 3-hydroxybutyrate was noted in subjects with a
sufficient endogenous insulin response (on dietary con-
trol or sulphonylureas), but not in subjects with insulin-
dependent type 2 diabetes, who are also known to have
greater ketogenesis after nighttime fasting (12). Duska
et al. [24] explored the relative impact of exogenous in-
sulin administration and endogenous insulin secretion
on plasma insulin levels in critically ill trauma patients
without diabetes. They found that, in such patients with-
out beta-cell dysfunction, the plasma insulin level is
mainly determined by the endogenous secretion rather
than by the insulin infusion, even during the acute phase
when exogenous insulin requirements were high.
Preserved beta-cell function with sufficient en-
dogenous insulin secretion could also explain the
relatively low blood ketone levels in our cohort and
the similar ketone kinetics in hyperglycemic patients
with and without exogenous insulin administration.
Moreover, among the few patients with marked keto-
nemia (n = 7) the majority was insulin-dependent
suggesting significant beta-cell failure. However, even
in this subgroup ketonemia resolved despite permis-
sive hyperglycemia.
The effect of fasting on urine ketone concentration
has been studied in a large Korean trial of 16,523 volun-
teers [25]. Only 8.8 % of all subjects developed ketonuria
after fasting overnight. Among those without ketonuria,
the prevalence of obesity and metabolic syndrome was
significantly higher and cholesterol levels, insulin levels
and body mass index (BMI) were more likely to be ab-
normal. A ketotic response to fasting could, therefore,
indicate a favorable metabolic state.
In addition to fasting, ketosis (and ketoacidosis) may
be caused by excessive alcohol consumption, severe hyp-
oxia, counter-regulatory hormone excess, catecholamine
infusion, parenteral nutrition, alkalosis, severe liver dis-
ease, and various inborn errors of metabolism [8, 9, 11,
18, 26, 27]. However, among our patients with acute
liver failure (n = 3), chronic alcohol intake (n = 4) and
acute alcohol intoxication (n = 1) only one patient
(acute-on-chronic liver failure) developed ketosis (peak
blood β-OHB level 1.4 mmol/l). Furthermore, catechol-
amine infusion or alkalosis was not associated with ele-
vated β-OHB levels in our study.
Table 3 Multivariable linear regression analysis showing the association with admission blood ketone level (mmol/l) in patients not
receiving insulin
Univariable analysis Multivariable analysis
Variable estimate (95 % CI) P value estimate (95 % CI) P value
Blood glucose level, per mmol/l 0.03 (−0.04 to 0.10) 0.35 0.03 (−0.05 to 0.12) 0.44
HbA1c, per % 0.16 (−0.08 to 0.40) 0.18 0.16 (−0.10 to 0.42) 0.21
Blood lactate, per mmol/l 0.02 (−0.08 to 0.12) 0.72 0.05 (−0.08 to 0.19) 0.41
Hematocrit, per % −0.02 (−0.06 to 0.03) 0.38 −0.03 (−0.08 to 0.01) 0.15
Catecholamine infusion
No Referent Referent
Yes −0.19 (−0.67 to 0.29) 0.43 −0.57 (−1.30 to 0.16) 0.12
Cardiopulmonary bypass surgery
No Referent Referent
Yes 0.44 (−0.02 to 0.91) 0.06 0.67 (−0.03 to 1.37) 0.06
APACHE III score (tertile)
23–49 Referent Referent
50–69 −0.68 (−1.23 to −0.13) 0.02 −0.41 (−1.14 to 0.33) 0.27
70–122 −0.30 (−0.85 to 0.25) 0.28 −0.29 (−0.54 to 1.12) 0.49
HbA1c glycated hemoglobin A1c, APACHE Acute Physiology and Chronic Health Evaluation
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In contrast, in our patients, cardiopulmonary bypass sur-
gery (performed during normothermia) appeared to be an
important trigger of ketogenesis. This finding is supported
by Hashimoto et al. [12]. In 24 patients, they compared the
arterial acetoacetate to β-OHB ratio (the so-called ketone
body ratio) between patients undergoing normothermic vs.
hypothermic cardiopulmonary bypass surgery. The ratio
decreased significantly in both groups suggesting reduced
mitochondrial redox potential favoring conversion to β-
OHB in such patients. Importantly, the decrease in ketone
body ratio was more pronounced after hypothermic bypass
indicating even greater β-OHB generation in that group.
Implications of study findings
Our finding that a BGL ≥10 mmol/l is not associated
with increased ketogenesis and that critical illness is as-
sociated with some degree of peri-admission ketosis irre-
spective of blood glucose level and insulin therapy
implies that a BGL range of 10–14 mmol/l in critically
ill diabetic patients may be associated with minimal add-
itional ketogenic metabolic stress.
Low nutritional intake in the hours and days before
ICU admission is a plausible explanation for the ob-
served early ketosis of critical illness in our population.
Indeed, although only about half of our patients re-
ceived nutrition, their caloric intake progressively in-
creased, which may have contributed to the observed
decline in ketone levels over time. In addition, it seems
that endogenous insulin secretion due to residual beta-
cell function may be sufficient to suppress ketogenesis
in patients not requiring insulin. This hypothesis is also
supported by a lack of correlation between the level of
ketonemia and blood glucose in our patients. In
addition, even in our patients with premorbid insulin-
dependent diabetes, the majority of which also required
insulin in ICU, early ketosis resolved despite sustained
hyperglycemia.
The clinical relevance of ketosis in ICU patients
remains unclear as recent studies suggest that β-
OHB could have anti-inflammatory effects by inhibit-
ing interleukin (IL)-1β and IL-18 production [28]. In
addition, ketone bodies provide important energy
source for vital organs not only during starvation
but also during stress-induced insulin resistance. Ke-
togenesis could, therefore, be an adaptive and pro-
tective response to critical illness.
Strengths and limitations
Our study has several strengths. We prospectively analyzed
a representative sample of patients with diabetes using the
same point-of-care analysis platform in every patient. The
setting of a tertiary hospital with a heterogeneous case mix
is likely to reflect the average ICU population. We per-
formed daily ketone measurements and simultaneously
tested urine samples for ketonuria during the entire ICU
stay or up to 10 consecutive days. We used a multivariable
model to assess the relationship between blood ketone
levels and glycemic control, markers of disease severity and
insulin administration. Our findings are robust and demon-
strate that blood ketone levels are unrelated to blood glu-
cose levels or insulin treatment in the critically ill diabetic
patient without diabetic ketoacidosis within the boundaries
of a liberal glucose protocol.
Our study has some limitations. First, it is observational
in nature and not a randomized controlled study. However,
our aim was to explore the prevalence of ketosis during lib-
eral glucose management of critically ill diabetic patients.
Second, this is a single-center study with only a limited
number of patients. However, we used solid methodology
and obtained more than 270 blood ketone measurements
and analyzed more than 100 hyperglycemic episodes. Third,
we used a semi-quantitative method to measure ketonuria.
However, given the inherent limitations [18, 27] of point-
of-care urine ketone tests, and in view of our results, it is
unlikely that quantitative methods would have influenced
our results. Yet, previous validation studies suggest that the
use of point-of-care instruments may overestimate true
blood β-OHB levels when hematocrit is below normal [14],
which was the case in most of our patients. Hence, we may
have overestimated the true ketosis prevalence. Fourth, we
did not measure plasma insulin concentrations or C-
peptide levels and were therefore not able to quantify beta-
cell function. Furthermore, although we lack data on
counter-regulatory hormone, FFA, amino acid and oxaloac-
etate levels, we assessed clinical variables relevant to keto-
genesis. Fifth, we did not measure glycosuria, which may be
particularly pronounced in critically ill patients during per-
missive hyperglycemia. The degree of glycosuria in such pa-
tients and its impact on patient-centered outcomes should
therefore be explored in future studies. Sixth, we did not
measure acetoacetate and acetone and could therefore not
quantify the total ketotic activity. Perturbations in the mito-
chondrial redox state during critical illness may alter the ra-
tio between acetoacetate and β-OHB [29]. However, we
performed repeated β-OHB measurements over several
days and observed a consistent and marked decline over
time. It is unlikely that unmeasured ketones would have a
different directional change over the corresponding time
frame. Finally, because the results of the daily ketone mea-
surements were documented on the observational chart,
we cannot exclude that these data influenced glucose man-
agement by clinicians. However, nursing and research staff
performed ketone measurements and documentation with-
out direct involvement of medical staff.
Conclusions
Ketosis in critically ill diabetic patients is common and
typically occurs in the period early after admission. Ketosis
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may be particularly pronounced following cardiopulmo-
nary bypass surgery. However, in critically ill diabetic pa-
tients, liberal glycemic control or insulin therapy does not
appear to be associated with ketosis. These findings sug-
gest that liberal glycemic control in these patients does
not cause additional ketotic stress and imply that factors
beyond glycemic control and insulin therapy may be more
important drivers of ketosis in such patients.
Additional file
Additional file 1: Table S1. Baseline characteristics of diabetic patients
with and without ketosis. Table S2. Glycemic control in diabetic patients
with and without ketosis. Table S3. Baseline characteristics of patients
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patients with American Diabetes Association (ADA) ketoacidosis. Figure
S1. Change in hematocrit over time for all study patients. Figure S2.
Daily mean caloric intake in patients receiving nutrition. (DOCX 90 kb)
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